CD68和bFGF在良性前列腺增生组织中的表达及临床意义

Expression and Clinical Significance of CD68 and bFGF in Benign Prostatic Hyperplasia Tissues

目的:探讨在良性前列腺增生患者组织中CD68和bFGF含量的变化及在临床的作用。方法:选择2016年6月至2017年12月在我院就诊,经病理组织活检确定为良性前列腺增生的68例患者作为观察组,52例前列腺炎症的患者为对照组。通过对其前列腺体积与IPSS、排尿症状及疼痛和不适评分,对两组进行分析;通过免疫组化实验,测定两组患者前列腺组织中CD68与bFGF含量变化情况。结果:与对照组相比,良性前列腺患者前列腺体积显著增大(P<0.05);IPSS与排尿症状及疼痛不适评分显著增多(P<0.05);疼痛和不适评分,两组患者差异无统计学意义(P>0.05)。免疫组化实验中,与对照组相比,良性前列腺患者组织中CD68与bFGF含量显著增加(P<0.05)。其良性前列腺状态均与组织中CD68与bFGF浓度呈正相关(r=0.426,0.401,P<0.05)。结论:良性前列腺患者组织中CD68与bFGF浓度的变化与其病理状态呈正相关,可为临床良性前列腺组织增生患者的诊断与治疗提供一定的参考。

Objective:To explore the changes of CD68 and bFGF levels in tissues of patients with benign prostatic hyperplasia and their effects in clinical practice.Methods:68 cases of patients with benign prostatic hyperplasia confirmed by pathological biopsy who were treated in our hospital from June 2016 to December 2017 were selected as observation group,and another 52 cases of patients with prostatic inflammation were included in control group.The prostate volume and IPSS,urinary symptoms and pain and discomfort scores were analyzed in the two groups.The changes of CD68 and bFGF levels in prostate tissues were determined by immunohistochemistry in the two groups.Results:Compared with control group,the prostate volume of benign prostate patients was increased significantly(P<0.05).IPSS,urinary symptoms and pain discomfort scores were increased significantly(P<0.05).There was no statistically significant difference in the pain and discomfort scores between the two groups(P>0.05).In the immunohistochemistry experiment,compared with control group,the levels of CD68 and bFGF in the tissues of patients with benign prostate were significantly increased(P<0.05).The benign prostate status was positively correlated with the concentrations of CD68 and bFGF in the tissues(r=0.426,0.401,P<0.05).Conclusions:The changes of CD68 and bFGF levels in tissues of patients with benign prostate are positively correlated with pathological status,and they may provide a reference for the diagnosis and treatment of patients with benign prostatic hyperplasia in clinical practice.